- AuthorisedTherapeutic exploratory (Phase II)
A Phase IIa Trial Evaluating the Efficacy of anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc) Resistant to Immunosuppressive Drugs. SCLEROCAR
This study is testing a new cell therapy called SCLEROCAR for severe systemic sclerosis. It aims to see if this treatment, using special T-cells, can improve skin and organ symptoms in people whose condition hasn't responded to usual medicines. Researchers want to understand its safety and how well it works.
For: Patients will be included with a stable but active disease (as defined Diagnosis of systemic · sclerosis according to ACR/EULAR classification by EUSTAR ≥2.5) or to patients with a · worsening disease despite low dose steroids and at least 2 immunosuppressive treatmentFrance - Active not recruitingPHASE1
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
This study is testing a new treatment called MB-CART19.1 for blood cancers like leukaemia and lymphoma that have come back or not responded to other treatments. It aims to find the safest dose for adults and children.
For: Acute Lymphoblastic Leukemia Recurrent · B-cell Lymphoma Recurrent · B-cell Lymphoma RefractoryGermany - RecruitingPHASE1, PHASE2
MB-CART19.1 in Refractory SLE
This study is testing a new treatment called MB-CART19.1 for severe lupus (SLE) that hasn't responded to other medicines. Researchers want to see if it's safe and effective in people aged 18 and over.
For: SLE - Systemic Lupus ErythematosusGermany